Telomir Pharmaceuticals, Inc.

NasdaqCM:TELO Stock Report

Market Cap: US$80.5m

Telomir Pharmaceuticals Management

Management criteria checks 2/4

Telomir Pharmaceuticals' CEO is Erez Aminov, appointed in Aug 2024, has a tenure of 2.08 years. total yearly compensation is $4.88M, comprised of 5.6% salary and 94.4% bonuses, including company stock and options. directly owns 10.64% of the company’s shares, worth $8.56M. The average tenure of the management team and the board of directors is 2.1 years and 2.3 years respectively.

Key information

Erez Aminov

Chief executive officer

US$4.9m

Total compensation

CEO salary percentage5.63%
CEO tenure2.1yrs
CEO ownership10.6%
Management average tenure2.1yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

Analysis Article • Aug 09

Will Telomir Pharmaceuticals (NASDAQ:TELO) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

CEO Compensation Analysis

How has Erez Aminov's remuneration changed compared to Telomir Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$52m

Mar 31 2026n/an/a

-US$9m

Dec 31 2025US$5mUS$275k

-US$10m

Sep 30 2025n/an/a

-US$11m

Jun 30 2025n/an/a

-US$16m

Mar 31 2025n/an/a

-US$12m

Dec 31 2024US$8mUS$106k

-US$17m

Compensation vs Market: Erez's total compensation ($USD4.88M) is above average for companies of similar size in the US market ($USD652.98K).

Compensation vs Earnings: Erez's compensation has been consistent with company performance over the past year.

CEO

Erez Aminov (48 yo)

2.1yrs
Tenure
US$4,880,350
Compensation

Mr. Erez Aminov is Chairman of the Board and Chief Executive Officer at Telomir Pharmaceuticals, Inc. since August 12, 2024. He is Chief Executive Officer of MIRA Pharmaceuticals, Inc. from April 28, 2023...

Leadership Team

NamePositionTenureCompensationOwnership
Erez Aminov
Chairman of the Board & CEO2.1yrsUS$4.88m10.64%
$ 8.6m
Andriy Mushak
Chief Financial Officerless than a yearno datano data
Itzchak Angel
Chief Scientific Advisor2.1yrsno datano data
2.1yrs
Average Tenure

Experienced Management: TELO's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Erez Aminov
Chairman of the Board & CEO2.1yrsUS$4.88m10.64%
$ 8.6m
Matthew Del Giudice
Independent Director2.5yrsno data0.018%
$ 14.6k
Edward MacPherson
Independent Director2.5yrsno data0.018%
$ 14.6k
Matthew Whalen
Independent Director2.1yrsno data0.018%
$ 14.6k
2.3yrs
Average Tenure
45yo
Average Age

Experienced Board: TELO's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 22:44
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Telomir Pharmaceuticals, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bradley SorensenZacks Small-Cap Research